82 results
8-K
EX-99
EDIT
Editas Medicine, Inc.
3 Oct 24
Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust
6:05pm
strategy.”
Under the terms of the agreement, Editas Medicine will receive an upfront cash payment of $57 million in exchange for up to 100% of certain
8-K
EX-99.1
EDIT
Editas Medicine, Inc.
7 Aug 24
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
7:06am
financial results for the second quarter 2024 and provided business updates.
“We made significant progress in all three pillars of our strategy this quarter … for an undisclosed indication by year-end.
The Company continues to pursue an in vivo strategy and approach aimed at driving functional upregulation of gene
8-K
EX-99.1
EDIT
Editas Medicine, Inc.
8 May 24
Editas Medicine Announces First Quarter 2024 Results and Business Updates
7:08am
strategy this quarter, including reni-cel, in vivo, and business development, including intellectual property,” commented Gilmore O’Neill, M.B., M.M.Sc
S-3ASR
fr6i2adwl tdbsc
28 Feb 24
Automatic shelf registration
5:13pm
S-8
1268zj0
28 Feb 24
Registration of securities for employees
4:39pm
8-K
EX-99.1
tkogiww8tdkdz85d
3 Nov 23
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
7:06am
424B5
wxerxi tvpz6m1
15 Jun 23
Prospectus supplement for primary offering
4:22pm
424B5
rmn mkcj6w3or4q78f6
14 Jun 23
Prospectus supplement for primary offering
5:20pm
8-K
EX-99.1
eq4z5p
5 May 23
Editas Medicine Announces First Quarter 2023 Results and Business Updates
7:16am